Nippon Zoki Eyes Alzheimer’s as New R&D Focus, First Up Is Label Expansion for Pain Med

Nippon Zoki President Ryusaku Konishi Nippon Zoki is looking to turn Alzheimer’s into a new R&D pillar alongside its current focus on pain and allergy, with an indication addition for Neurotropin being furthest along in development and more drug candidates...read more